AU2001286302A1 - High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor - Google Patents

High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor

Info

Publication number
AU2001286302A1
AU2001286302A1 AU2001286302A AU8630201A AU2001286302A1 AU 2001286302 A1 AU2001286302 A1 AU 2001286302A1 AU 2001286302 A AU2001286302 A AU 2001286302A AU 8630201 A AU8630201 A AU 8630201A AU 2001286302 A1 AU2001286302 A1 AU 2001286302A1
Authority
AU
Australia
Prior art keywords
coding sequence
genetically engineered
retroviral vector
cellularnon
high efficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286302A
Inventor
Sun Young Kim
Jun Tae Lee
Seung Shin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helixmith Co Ltd
Original Assignee
Viromedica Pacific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromedica Pacific Ltd filed Critical Viromedica Pacific Ltd
Publication of AU2001286302A1 publication Critical patent/AU2001286302A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a safe and highly efficient retroviral vector derived from the MLV (murine leukemia virus) for use in gene therapy, which lacks viral coding sequences but contains the genetically engineered EF Ialpha non-coding sequence harboring splicing acceptor.
AU2001286302A 2000-09-08 2001-09-08 High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor Abandoned AU2001286302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR0053613 2000-09-08
KR10-2000-0053613A KR100373821B1 (en) 2000-09-08 2000-09-08 High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splice acceptor
PCT/KR2001/001515 WO2002020810A1 (en) 2000-09-08 2001-09-08 High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splicing acceptor

Publications (1)

Publication Number Publication Date
AU2001286302A1 true AU2001286302A1 (en) 2002-03-22

Family

ID=19688348

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286302A Abandoned AU2001286302A1 (en) 2000-09-08 2001-09-08 High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor

Country Status (9)

Country Link
US (1) US7049143B2 (en)
EP (1) EP1326988B1 (en)
JP (1) JP3921445B2 (en)
KR (1) KR100373821B1 (en)
CN (1) CN1206359C (en)
AT (1) ATE470717T1 (en)
AU (1) AU2001286302A1 (en)
DE (1) DE60142348D1 (en)
WO (1) WO2002020810A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450688A (en) * 2005-05-11 2009-01-07 Viragen Inc Ovalbumin promoter constructs for retroviral vectors
EP2082043A4 (en) * 2006-10-10 2010-03-24 Viromed Co Ltd Expression vectors with improved safety
KR101390967B1 (en) * 2006-10-10 2014-05-14 주식회사 바이로메드 Retroviral vectors with improved safety
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
WO2012157743A1 (en) * 2011-05-19 2012-11-22 タカラバイオ株式会社 Retroviral vector carrying exogenous sd-sa
WO2012157742A1 (en) * 2011-05-19 2012-11-22 タカラバイオ株式会社 siRNA EXPRESSION RETROVIRAL VECTOR
WO2014162318A2 (en) * 2013-03-30 2014-10-09 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
WO2015053398A1 (en) * 2013-10-11 2015-04-16 タカラバイオ株式会社 High-titer retrovirus vector
AU2019361631A1 (en) 2018-10-19 2021-06-03 Cartexell Inc. Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
US20220010332A1 (en) * 2020-07-08 2022-01-13 Neuracle Genetics Inc. Intron fragments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
KR20000006334A (en) 1998-06-26 2000-01-25 이선경 High efficiency retroviral vectors that contain none of viral coding sequences

Also Published As

Publication number Publication date
WO2002020810A1 (en) 2002-03-14
CN1388829A (en) 2003-01-01
ATE470717T1 (en) 2010-06-15
CN1206359C (en) 2005-06-15
KR20010069245A (en) 2001-07-25
JP3921445B2 (en) 2007-05-30
US20030166251A1 (en) 2003-09-04
DE60142348D1 (en) 2010-07-22
EP1326988A1 (en) 2003-07-16
US7049143B2 (en) 2006-05-23
KR100373821B1 (en) 2003-02-26
JP2004508047A (en) 2004-03-18
EP1326988B1 (en) 2010-06-09
EP1326988A4 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2001286302A1 (en) High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
WO2004067710A3 (en) Compositions and methods for tissue specific targeting of lentivirus vectors
IL174653A0 (en) Promoters for expression in modified vaccinia virus ankara
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
GR3033104T3 (en) Polyphenol oxidase genes.
GB2376687B (en) Herpes viruses for immune modulation
WO2003066810A3 (en) Recombinant bovine immunodeficiency virus based gene transfer system
AU4835696A (en) Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells, therapeutic and vaccine applications.
DK0906443T3 (en) Generation of replicating molecules in vivo
WO1998017814A3 (en) Gene expression and delivery systems and uses
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
IL139604A0 (en) Novel peptides
AU9393101A (en) Scorch-delaying composition
EP1167523A3 (en) Insertion sequence elements derived from ralstonia solanacearum
WO2002028423A8 (en) Stabilisation of plasmid inheritance in bacteria by preventing multimerisation
GB2341391B (en) Cloning of UDP-galactose epimerase
MXPA02011570A (en) Modified sulfonamide polymers.
WO2003046138A3 (en) Genetically stable expression vector
WO1998018950A3 (en) AAV-DNA helper virus sequences
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
DE60114835D1 (en) RECOMBINANT PLASMID PDSBCM, WITH THIS TRANSFORMED MICROORGANISM AND METHOD FOR PRODUCING AN ALKALINE VAPK PROTEASE
Monroe Within the Walls.
WO2001066715A3 (en) Rapid generation of recombinant adenoviral vectors